Related Experiment Video
Updated: May 15, 2025

Modeling Age-Associated Neurodegenerative Diseases in Caenorhabditis elegans
Published on: August 15, 2020
Conformational Constraint for Prevention of Aging of Organophosphate-Inhibited Acetylcholinesterase
Francine S Katz1,2,3, Ilya Trakht1, Stevan Pecic1,4
1Department of Medicine, Columbia University Irving Medical Center, 630 W 168th Street, BB8-444, New York, NY, 10032, USA.
Abstract:
The covalent inhibition of acetylcholinesterase (AChE) by organophosphate compounds (OPCs) prevents the hydrolysis of the neurotransmitter, acetylcholine, and results in overstimulation of muscarinic and nicotinic receptors leading to severe cholinergic crisis. To treat toxic exposure to OPCs, the focus has been on using reactivator compounds (e.g., oximes) to reverse the adduct formation in the enzyme's active site, and to release the regenerated, active form of AChE. However, the interaction between the OPC inhibitor and the enzyme is usually followed by a secondary dealkylative reaction in which the OPC "ages", that is, produces an oxyanion on the phosphoryl group that cannot be recovered with standard reactivators. The unexpected discovey that immobilization of AChE prevented aging of OPC adducts led to the hypothesis that the inhibition and recovery pathways in AChE could be regulated by allosteric effectors that bind to the enzyme at a distance away from the site of inhibition. To demonstrate this, resistance to aging was replicated using bifunctional crosslinking of AChE in solution. This work provides the foundation to expand these principles to other potential effectors.
More Related Videos
08:16Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
Published on: September 21, 2021
05:57Author Spotlight: In Silico Creation and Impact of Carbonylated Amino Acids on Protein Structure and Function
Published on: April 26, 2024
Related Concept Videos
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Cholinesterases: Distribution and Function